Cocrystal Pharma Appoints Carol Brosgart to Board

Cocrystal Pharma, Inc., a clinical-stage biotechnology company developing antiviral therapeutics, announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings decades of experience in antiviral therapy, epidemiology, and biopharma advisory. She previously spent more than a decade at Gilead Sciences, contributing to the development and FDA approval of antiviral therapies Viread and Hepsera. She currently serves on the boards of Rhythm Pharmaceuticals, Eradivir Biotech, and Merlin Biotech, and previously held board positions at Abivax, Mirum Pharmaceuticals, Bicara Therapeutics, and Juvaris. She is also a member of the Board of Directors of the Hepatitis B Foundation and has served as a Senior Advisor to the CDC and Centers for Disease Control and Prevention. Cocrystal's Chairman Roger D. Kornberg and CEO James Sapirstein welcomed her appointment, highlighting her clinical and scientific insights as the company advances CDI-988 for norovirus and its broader antiviral pipeline.